- Home
- EXAS vs CZR Comparison
EXAS vs CZR Comparison
Compare EXAS & CZR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EXAS
- CZR
- Stock Information
- Founded
- EXAS 1995
- CZR 1937
- Country
- EXAS United States
- CZR United States
- Employees
- EXAS N/A
- CZR N/A
- Industry
- EXAS Medical Specialities
- CZR Hotels/Resorts
- Sector
- EXAS Health Care
- CZR Consumer Discretionary
- Exchange
- EXAS Nasdaq
- CZR Nasdaq
- Market Cap
- EXAS 10.7B
- CZR 5.4B
- IPO Year
- EXAS N/A
- CZR 1989
- Fundamental
- Price
- EXAS $51.91
- CZR $30.16
- Analyst Decision
- EXAS Strong Buy
- CZR Strong Buy
- Analyst Count
- EXAS 20
- CZR 14
- Target Price
- EXAS $70.26
- CZR $43.64
- AVG Volume (30 Days)
- EXAS 2.8M
- CZR 5.6M
- Earning Date
- EXAS 07-30-2025
- CZR 07-29-2025
- Dividend Yield
- EXAS N/A
- CZR N/A
- EPS Growth
- EXAS N/A
- CZR N/A
- EPS
- EXAS N/A
- CZR N/A
- Revenue
- EXAS $2,828,128,000.00
- CZR $11,297,000,000.00
- Revenue This Year
- EXAS $14.58
- CZR $3.26
- Revenue Next Year
- EXAS $12.75
- CZR $2.46
- P/E Ratio
- EXAS N/A
- CZR N/A
- Revenue Growth
- EXAS 11.57
- CZR N/A
- 52 Week Low
- EXAS $39.97
- CZR $21.40
- 52 Week High
- EXAS $72.83
- CZR $45.93
- Technical
- Relative Strength Index (RSI)
- EXAS 44.34
- CZR 57.51
- Support Level
- EXAS $52.00
- CZR $29.01
- Resistance Level
- EXAS $55.90
- CZR $31.58
- Average True Range (ATR)
- EXAS 2.31
- CZR 1.06
- MACD
- EXAS -0.04
- CZR 0.20
- Stochastic Oscillator
- EXAS 24.90
- CZR 64.51
About EXAS Exact Sciences Corporation
Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is also developing liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening.
About CZR Caesars Entertainment Inc.
Caesars Entertainment includes about 50 domestic gaming properties across the Las Vegas (49% of 2024 EBITDAR before corporate expenses) and regional (46%) markets. Additionally, the company hosts managed properties and digital assets that produced marginal EBITDA in 2024. Caesars' US presence roughly doubled with the 2020 acquisition by Eldorado, which built its first casino in Reno, Nevada, in 1973 and expanded its presence through prior acquisitions to over 20 properties before merging with legacy Caesars. Caesars' brands include Caesars, Harrah's, Tropicana, Bally's, Isle, and Flamingo. Also, the company owns the US portion of William Hill (it sold the international operation in 2022), a digital sports betting platform.